Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways by unknown
Major Histocompatibility  Complex Class R-restricted 
Presentation  of an Internally  Synthesized  Antigen 
Displays  Cell-type  Variability  and Segregates  from the 
Exogenous  Class II and Endogenous Class I 
Presentation  Pathways 
By George E. Loss, Jr.,* Chester G. Elias,~ Patrick E. Fields,r 
Randall K. Pdbaudo,$  Maureen McKisic,~ and Andrea J. Sant~ 
From the Departments of *Surgery and *Pathology, the University of Chicago, Chicago, Illinois 
60637; and the SMolecular Biology Section, LaboraWry of Immunology, National Institute of 
Allergy and Infectious Diseases, National Institutes of Health, Bethescla, Maryland 20892 
Sllmmary 
Although reported examples of endogenous antigen (Ag) presentation by major histocompatibility 
complex (MHC) class II molecules have increased, the mechanisms governing this process remain 
poorly defined. In this communication, we describe an experimental system designed to examine 
the mechanisms governing class II presentation of internal Ag. Our target peptide is processed 
from a transmembrane protein constitutively expressed by a variety of nucleated cells (MHC 
class I, H-2La), is naturally displayed by MHC class II molecules in vivo, and is recognized by 
a class II-restricted,  CD4 + T cell hybridoma. Our results indicate that presentation of the L  d 
target Ag is independent of its plasma membrane expression,  may not involve  endosomal proteolysis, 
and thus may be distinct from the classically defined class II presentation pathway. In addition, 
the observations that L  a presentation  does not require a functional  TAP-1 complex,  is not 
blocked by invariant chain,  and cannot utilize  cytoplasmic forms  of H-2L  a,  suggest  that a 
classical class I pathway is not involved in this presentation event. Finally, our data suggest that 
different cofactors participate in MHC class II presentation of exogenous and endogenous Ag, 
and that disparate Ag presenting cells, such as B, T, and pancreatic islet cells, may differentially 
express these two class II pathways of Ag presentation. 
T  lymphocytes recognize  Ag as peptide fragments  as- 
sociated with MHC molecules on the surface of APC 
(1, 2). MHC class II molecules have the specialized capacity 
to present peptides generated from extracellular Ag which 
enter the cell by endocytosis (3, 4). The resulting class II-pep- 
tide complexes, products  of the endosomal-lysosomal pro- 
cessing pathway, are recognized by CD4 + T cells. In con- 
trast, class I MHC molecules  primarily present peptides derived 
from proteins with access to the cytosol and its resident pro- 
teolytic machinery. Resulting class I-peptide complexes are 
important in directing the immune response of CD8 + cyto- 
lytic T  lymphocytes against viraUy infected cells. 
It has become increasingly clear, however, that class II can 
efficiently bind and present peptides derived from proteins 
synthesized within the APC (5-13). This suggests that, in 
the absence of receptor-mediated uptake of extracellular pro- 
tein, internally synthesized  proteins may be the principal source 
of class II peptides. Like typical extracellular Ag, intracel- 
lular Ag could potentially access the endocytic processing 
pathway by internalization  from the plasma membrane, by 
secretion and pinocytosis, or by receptor-mediated endocy- 
tosis. Internal Ag might also access the endosomal/lysosomal 
pathway by  direct  sorting from the trans-Gol~  network 
(TGN) 1, by heat shock protein (HSP)-mediated uptake from 
the cytosol (14), or by autophagy (15). Although the extent 
to which class II displays peptides derived from internally 
synthesized proteins is becoming increasingly apparent, the 
mechanisms  governing their  presentation  remain  poorly 
defined. Our understanding of class II presentation is largely 
derived from studies involving exogenous protein Ag. Interest- 
ingly, these studies have implicated the likely importance of 
several protein cofactors in class II Ag presentation including 
1 Abbreviations  used in tkispaper: ER, endoplasmic reticulum; GAM, goat 
anti-mouse Ig; gli, genomic invariant chain; hMYO, horse myoglobin; 
HSP, heat shock protein; Ii, invariant chain; MXH, mycophenolic acid, 
xanthine, and hytmxanthine; MYOT, tryptic digest ofMYO; OVAT, tryptic 
digest of OVA; TGN, trans-Gol#  network. 
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protein(s) encoded by genes within the MHC (18). It is not 
known if the same protein cofactors will regulate the presen- 
tation of internal versus external Ag or if these cofactors will 
vary with cell type. 
To examine the regulation of class II presentation of an 
intracellular Ag, we developed an experimental system in which 
a peptide processed  from an MHC class I molecule (L  a) is 
displayed by the murine class II molecule I-A  d (19). The 
I-Ad/L  a  peptide  complex  is  recognized by  a  T  cell  hy- 
bridoma  derived  from  the  Ld-negative,  BALB/c-H-2  am2 
mouse. This system affords us the opportunity to examine 
presentation of a typical ubiquitous Ag which, under physi- 
ologic levels of expression, gains access to class II indepen- 
dently of an ongoing viral infection. Using recombinant DNA 
technology and cellular transfection techniques, we altered 
(a) subcellular  localization of the class I target Ag; (b) lin- 
eage of the cell expressing  both the target Ag and class II 
restriction element; and (c) expression of Ii within the APC, 
all parameters of potential relevance for Ag presentation and 
subject to variation in vivo.  Collectively, our data suggest 
a pathway of endogenous dass II Ag presentation, distinct 
from both the dassicaUy described class I and II presentation 
pathways, which may function selectively  in  the APC of 
different lineages. 
Materials and Methods 
Animals.  BALB/c  mice were purchased from the Jackson Lab- 
oratory (Bar Harbor, ME). H-2 Ld-negative  BALB/c-H-2  am2 (dm2) 
mice (20) were bred at the University of Chicago in a barrier fa- 
cility from stock provided by Dr. Roger Melvold (Northwestern 
University, Chicago, IL). 
Tissue Culture  Reagents.  Cell lines were maintained at 37~  and 
5% COs in supplemented R.PMI as described (21) plus selection 
drugs G418 (0.2 mg/ml), MXFI (6/~g/ml mycophenolic  acid, 0.3 
mg/ml xanthine, and 15/~g/ml hypoxanthine) (Sigma Chemical 
Co., St. Louis, MO), and histidinol (5 mM) as indicated. All media 
and supplements were purchased from GIBCO BRL (Grand Is- 
land, NY) unless otherwise noted. The synthetic peptide corre- 
sponding  to  amino  acids 61-85 of L  d was  synthesized at  the 
University of Chicago Cancer Center. Chicken OVA and horse 
myoglobin (hMYO) were purchased from Sigma Chemical Co. and 
tryptic digests of each (OVAT and MYOT, respectively)  were pre- 
pared as described by Shimonkevitz et al. (22), Purified soluble 
Ld/Q10 was provided by L. Boyd  and D. Margulies (National In- 
stitutes of Health [NIH]). 
mAbs.  mAb-producing  hybridomas  reactive with  I-A  d 
(MKD6 [23], M5/114 [241, K24-199 [25], 40B [26]); I-E (14-4-4S 
[27]); I-A  k (10.2-16 [28]); H-2K  k (16-1-2N [25], 16.1.11N [25]); 
and with H-2L  a (30.5.7 [29], 28.14.8 [29]) were acquired from 
American Type Culture Collection (Rockville, MD). 64.3.7 (anti- 
L  d [30]) was provided by D. Sachs (NIH),  whereas F23.1 (anti- 
TCR Vfl8 [31]) culture supematant was kindly provided  byJ. Blue- 
stone (University of Chicago). Ii-reactive  mAbs (P4H5 [32], IN-1 
[33]) were gifts fromJ. Miller (University of Chicago). The mAbs 
2.43 (anti-CD8 [34]) and GK1.5 (anti-CD4 [35]) were provided 
by F. Fitch (University of Chicago). Antibodies were used as cul- 
ture supernatants except for in vivo T cell depletion experiments 
where an ascites preparation of 2.43 was used. 
Flow Cytometry.  Cells  were evaluated for MHC molecule cell 
surface expression using mAb as culture supernatants and a sec- 
ondary staining reagent (FITC-labeled  goat anti-mouse Ig [FITC- 
GAM]; Cappel Laboratories, Cochranville, PA) as described (21), 
and analyzed on a FACScan  |  cytofluorimeter (Becton Dickinson 
& Co., Mountain View, CA). Background  control fluorescence  was 
measured using an irrelevant mAb plus FITC-GAM or medium 
alone and FITC-GAM (as indicated in each figure, see Results). 
Gene Constructs.  The  L a genomic  done pLa.4 was  kindly 
provided by T. Hansen (Washington University, St. Louis, MO) 
and pLa/QIO (36) was provided by D. Margulies. An L  d eDNA 
(37) was cloned into the Lk444 (38) vector utilizing the fl-actin 
promoter  (pLd444), and  a  leaderless L  a construct  (pLa,~) was 
generated from pLa444 utilizing PCK mutagenesis to remove the 
sequence encoding the leader peptide from L  d and then adding an 
initiation sequence (39) 5' to the c~1 domain of H-2L  d. The altered 
L  d gene was sequenced  and subsequently  subcloned into the Lk444 
fl-actin expression vector. 
Transfectants.  The class II-negative cell line DAP.3 was trans- 
fected with I-A  d c~ and fl chain genes and the selection marker 
Ecogpt by the calcium  phosphate  method (40) and selected  in MXH. 
Supertransfection of bA  d positive cells (DAP-AD) was  subse- 
quently performed using a second selection  marker (pSV2neo) and 
either pLa.4, pLd444, pLa/QlO, or the pL~rt construct. Cells resis- 
tant to G418 were then subcloned or sorted for cell surface expres- 
sion of H-2L  d. DAP-LD and DAP-LD/Q10 were derived  by trans- 
fection of DAP.3 with pLd.4 or pLd/QlO, respectively. Those cells 
transfected with pLa/Q10 were subcloned by limiting dilution and 
screened for La/Q10 expression by immunoprecipitation and in- 
tracytoplasmic staining. 
Ltk-  cells transfected with  I-A  d only (LAD)  or  I-A  a plus 
genomic Ii (LADgIi) (41), the thymic tumor cell line EL4 trans- 
fected by electroporation with I-A  a and ECOgpt (ELAD) (42), and 
a  t~TC-3 (H-2  d)  insulinoma  cell line  transfected  with  I-A  a 
(fl-AD) (43) were generously provided by J.  Miller. LAD and 
LADgIi were subsequently transfected with genomic L d and the 
selection marker pSV2his (44) by the calcium phosphate method 
yielding LAD-LD (MGT1) and LADgIi-LD (MGT2), respectively. 
Sublines were selected in MXH, G418, and histidinol. Transfec- 
tants matched for class II and L  d expression were obtained by mAb 
and magnetic bead cell sorting. The EL4 cell line (ELAD) was sub- 
sequently supertransfected with genomic L  a (pLa.4) and pSV2neo 
by electroporation, and the resulting cells (ELAD-LD) selected in 
G418 and MXH. 
The embryonic  cell line EE2H3 (H'2 k) originally  derived  by Sil- 
verman et al. (45) and provided by J. Bluestone was transfected 
with I-A  a, genomic L  d, and pSV2neo by the calcium phosphate 
method, EE2H3-ADLD transfectants  (GEE.4) were selected  in G418 
and sorted for I-A  a expression. 
T Cell Lines and Hybridomas.  The CD4 + T cell clones 93.1 
(bA  d restricted, L  a peptide 61-85 specific) and 50.13 (H-2L  a re- 
stricted) were obtained from dm2 mice immunized with full thick- 
ness BALB/c skin grafts (19). T cell clones were fused with the 
hypoxanthine guanine phosphoribosyl transferase  (HGPRT) nega- 
tive thymoma line or- fl- BW5147 by fusion with polyethylene 
glycol (PEG 1500; Boehringer Mannheim, Mannheim, Germany) 
(46). Hybridomas were selected with HAT (GIBCO BILL) and 
plated at limiting dilution. Hybridomas from the 93.1 clone (GTH) 
were screened on irradiated (2,000 rad) BALB/c splenocytes and 
DAP-ADLD transfectants  for their ability to produce lymphokines, 
whereas those from 50.13 (EM50.13) were screened on A20 and 
DAP-LD. 
A CD4 +, Ld-reactive  bulk T cell population was generated by 
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splenocytes. In vivo T cell depletion was performed as described 
(19) and  CD8-depleted  dm2  mice were then  immunized  in- 
traperitoneaUy with 3  x  107 irradiated BALB/c splenocytes. 11 d 
after immunization, spleen cells from the dm2 mice were subjected 
to in vitro depletion using anti-CD8 mAb (2.43), anti-Ia mAbs 
(MKD6, K24-199, M5/114, 14.4.4S), and Low-Tox-M  rabbit com- 
plement (Cedarlane  Laboratories  Ltd., Hornby, ON, Canada). Ap- 
propriate cellular depletion was confirmed by flow cytometry. For 
stimulation of the dm2 anti-BALB/c bulk T cell population, 2.5 
x  10  s T cells were placed in microwells with 5  x  103 mitomycin- 
treated L cells or 5  x  10  s irradiated splenocyte APC. After 48 h 
of incubation at 37°C, cultures were pulsed with 1/~Ci/well of 
[3H]thymidine  and T cell proliferation was measured as a function 
of [3H]thymidine incorporation. Cultures using L cells as APC 
were performed in the presence of the prostaglandin inhibitor in- 
domethacin (5/~g/ml). 
T Cell Hybridoma Assays.  APC used at the concentrations in- 
dicated (see figures) and hybridomas  used at 5-7.5  x  104 cells/well 
were cocultured for 16-20 h and supernatants  tested for lymphokine 
content by culture with the growth factor-dependent T cell line 
CTLL as described (19). Results appear as mean cpm of triplicate 
cultures unless otherwise noted. 
Cxtokine Induction of MHC Expression.  APC were treated for 
the times indicated with 10 U/ml of  IFN-3, (Genzyme  Corp., Cam- 
bridge, MA) and 100 U/ml of TNF (gift of Dr. Hans Schreiber, 
University of Chicago). Before initiation of the Ag presentation 
assay, APC were washed thoroughly and an aliquot of APC stained 
to evaluate  cytokine-induced changes in surface MHC expression. 
Coculture Assays.  Irradiated dm2 or BALB/c splenocytes  were 
incubated with La/QIO containing supernatant as described (see 
Fig. 3 legend). Ceil'cell coculture experiments were performed in 
25 cm  2 culture flasks using equal numbers of DAP-AD and DAP- 
LD/Q10,  as indicated (see Fig. 3 legend). L. Boyd and D. Mar- 
gulies kindly provided us with purified Ld/Q10 and performed 
quantitative analysis of Ld/Q10 contained in supernatants from 
DAP-ADLD/Q10 and DAP-LD/Q10 cultures using an ELISA  assay. 
Metabolic Labeling~ Immunoprecipitation, and SDS-PAGE.  Meta- 
bolic labeling and immunoprecipitation  of proteins from transfected 
cells was performed as previously described (47). Immunoprecipi- 
tated material was analyzed  by SDS-10% PAGE. All SDS gels were 
treated with EN3HANCE (New England Nuclear, Boston, MA), 
dried, and autoradiographs prepared at  -70°C. 
Resulm 
The T  Cell Hybridoma  GTH Maintains  the Reactivity  Pat- 
tern of the Parent T  Cell Clone.  We generated a T  cell hy- 
bridoma from the clone 93.1 and ct-,/~- BW5147 (19). The 
use of a hybridoma diminishes the contribution of accessory 
molecules to T  cell stimulation and provides a more direct 
method of assessing peptide-MHC complex expression.  Fig. 
1 demonstrates stimulation of one such T  cell hybridoma 
(GTH) by L cells (DAP.3:H-2  ~, class II-) transfected with 
both the target Ag (L  d) and the I-A  a restriction element 
(DAP-ADLD).  This response was  specifically  blocked by 
mAbs  directed  against  I-A  a.  GTH  also  produced  lym- 
phokines in response to a  synthetic peptide of L  d (amino 
acids 61-85)  added to either live or fixed I-Aa-bearing APC 
that lack L a. These results establish that GTH is restricted 
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Figure 1.  Expression  of both I-A  d and L  d is required for stimulation 
of GTH. 5 x 104 of indicated APC were incubated  with 5 x 104 GTH 
T cell hybridomas  for 18 h in an Ag presentatio~ assay  as previously  de- 
scribed. Shown are  cpm  of [3H]thymidine incorporated by growth 
factor-dependent  CTLL.  The ability  of anti-I-A  d (MKD6, M5/114) mAbs 
and the inability  of anti-L  a (30.5.7) and anti-KkD  k (16.1.2 N) mAbs to 
block the stimulation  of GTH are shown above. 
by I-A  d and specific for a fragment of L a, mirroring the re- 
activity of the parent dm2-derived T  cell clone. 
Cell Surface Expression of H-2L d Is Not Required for Pro- 
cessing and Presentation by I-A d.  The most obvious route for 
an endogenously synthesized transmembrane Ag to gain access 
to the endocytic processing compartment is by internaliza- 
tion from the plasma membrane. To determine whether cell 
surface expression of L  a is required for processing and pre- 
sentation of the L d peptide, a gene encoding a soluble form 
of the target Ag (La/Q10) was transfected into DAP.3 with 
or without the I-A  a restriction element. Ld/Q10 (comprised 
of the NH~-terminal or1 and c~2 domains of L a and the c~3 
COOH-terminal domain of Q10  [36])  associates with B2 
microglobin, maintains normal ctl and a2 antibody epitopes, 
lacks a transmembrane domain, and is thus not expressed at 
the cell surface, but is secreted into the extracellular medium. 
Fig.  2 A  shows metabolically labeled La/Q10 precipitated 
from whole L cell transfectant lysates (lane 3) or from the 
extracellular  medium (lane 9). As expected,  Ld/Q10 was not 
detected at the cell surface by immunofluorescence staining 
(Fig.  3 D),  nor was an La-restricted alloreactive  T  cell hy- 
bridoma (EM50.13) stimulated by Ld/Q10 transfectants  (data 
not shown). Despite a lack of L  d surface expression, DAP- 
ADLD/Q10 transfectants processed and presented the target 
L  a peptide to GTH as effectively as DAP-ADLD (Fig. 2 B). 
To further test the possible  involvement of a cell surface 
intermediate in  L  d presentation,  we  sought  to  alter  pro- 
cessing of L  a and La/Q10 with anti-L  a antibodies. If tran- 
sient surface or extracellular expression of L  d is critical for 
generation of the GTH-specific peptide, then addition of anti- 
L  d antibody might be expected to modulate L a Ag presen- 
tation. Despite using a broad panel of anti-L  d antibodies of 
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Figure  2.  Cell surface expression of L  d is not required for effective pro- 
cessing and  presentation of stimulatory determinant(s)  to  GTH.  (.4) 
Ld/Q10 is expressed at high levels intracellularly and in the extracellular 
medium of  DAP-ADLD/Q10 transfectants. DAP-AD cells supertransfected 
with either wild-type genomic L  d (lanes 4-6 and 10-12) or La/Q10 (lanes 
1-3 and 7-9) were labded for 12 h with [3H]leucine followed by a 2.5-h 
chase period. Immunoprecipitates from cell lysates (hnes 1-6) or from the 
culture medium (lanes  7-12)  were analyzed by SDS-10%  PAGE under 
reducing conditions. L  a molecules (arrows)  were immunoprecipitated with 
the mAb 30.5.7 (lanes 3, 6, 9, and 12). A lower molecular weight form 
of L  d present in the cell-associated lysates from both Ld/Q10 (lane 3) and 
genomic L d (lane 6) transfectants  represents  an immature form of the 
target Ag (48). Class II c~ and/3 chains (small and large brackets, respec- 
tively) were isolated with the mAb M5/114 (lanes 2, 5, 8, and 11). Con- 
trol precipitates using the irrelevant  mAb 10.2-16 (anti-I-A  k) are shown 
in lanes 1, 4, 7, and 10 for comparison of background bands. (B) DAP- 
ADLD and DAP-ADLD/Q10 APC were plated at 5  x  104 cells per well 
with an equal number of l-Aa-restricted, L  d peptide-specific  T  cell hy- 
bridomas (GTH) and incubated at 37~  for 18 h. Supernatants  were as- 
sayed for lymphokine content. Shown are mean cpm of duplicate cultures 
resulting from [3H]thymidine incorporation by CTLL in the presence of 
various concentrations of supernatant from the original APC assay. 
varying domain specificity and increasing antibody incuba- 
tion times, no specific modulation of L d Ag presentation was 
detected for either DAP-ADLD or DAP-ADLD/Q10 (data 
not shown). 
Presentation of the Secreted Ld/QIO Does Not Occur by In- 
ternalization from the Medium.  To test the possibility that 
secreted Ld/Q10 enters the class II Ag processing compart- 
ment by reuptake from the extracdlular medium, DAP-AD 
cells were incubated for 4 d, or irradiated din2 splenocytes 
(spin) were incubated overnight, with supernatant (SN) con- 
taining  La/Q10.  Neither  DAP-AD  nor  dm2  splenocytes 
stimulated GTH when pulsed with Ld/Q10 (Fig. 3, A  and 
B). The La/QlO-contfLffmg  supernatant used in these experi- 
ments was freshly obtained from confluent flasks containing 
DAP-ADLD/Q10 transfectants,  and cells from these same 
flasks were effective stimulators of GTH (Fig. 3, A  and B, 
shaded bars). Moreover, purified La/Q10 added to DAP-AD 
at a concentration 1,000-fold higher than that maximally ac- 
cumulated in the medium of Ld/Q10-secreting cells did not 
stimulate GTH (Fig. 3 E). To test whether suboptimal levels 
of peptide-MHC complexes were expressed by DAP-AD in 
the presence  of purified soluble Ld/Q10,  we performed a 
dose-response assay using synthetic L  a 61-85 peptide. We 
reasoned that if a significant but subthreshold level  of processed 
L  d  peptide  was  displayed  in  the  presence  of  high-dose 
Ld/Q10, then less L  d 61-85 peptide should be required to 
stimulate GTH. This should result in a shift to the left in 
the L  d 61-85 peptide dose-response curve. No such shift in 
the peptide dose-response curve was evident in the presence 
of exogenously added soluble Ld/Q10 (Fig. 3 E,  ￿9  vs D). 
These results strongly suggest that the epitope recognized 
by GTH is not readily generated after endocytosis of target 
Ag from the culture medium. 
Although exposure of APC to extracellular  La/Q10 did 
not result in detectable levels of GTH-specific peptide, we 
considered the possibility that cell-ceU contact might facili- 
tate Ld/Q10 uptake. To address this possibility,  cells trans- 
fected with La/Q10 alone (DAP-LD/Q10) were cocultured 
with DAP-AD. APC from these mixed cultures did not stimu- 
late GTH, indicating that presentation of the determinant 
recognized by GTH  does not occur by uptake of La/Q10 
from the medium or from adjacent cells (Fig. 3 B, open bar). 
To test whether the secreted L  a Ag could serve as sub- 
strate for the generation of peptide epitopes other than that 
recognized by GTH, we generated a polyclonal dm2 anti- 
BALB/c CD4 + T  cell population. As shown in Fig.  3 C, 
CD4 §  T  cells obtained from immunized dm2 mice were 
able to recognize and proliferate in response to I-Aa-bearing 
APC cocultured with either DAP-LD/Q10 cells or superna- 
tant containing La/Q10. This suggests that a recognizable 
epitope(s) is generated from Ld/Q10 after endocytosis,  and 
that this epitope is likely distinct from that generated from 
internally synthesized Ld/Q10. 
In summary, our results  using the Ld/Q10 construct in- 
dicate that cell surface expression of the target Ag is not re- 
quired, nor is addition of the target Ag to the extraceUular 
medium sufticient,  for generation of peptide-class II com- 
plexes recognized by GTH. This suggests that the L  a pep- 
tide is generated during intracellular biosynthesis and trans- 
port of the newly synthesized target Ag.  Thus, internally 
derived L  d either accesses the class II endosomal processing 
compartment with far greater efticiency than exogenous Ag, 
or it employs proteolytic machinery different from that used 
to process extracellular  Ag taken up by endocytosis. 
A  Cell Line Deficient in Presentation of Exogenous Nominal 
Ag Efl;ciently Presents the Endogenously Derived L d Peptide.  To 
explore the possibility that L  d and exogenous Ag utilize dis- 
tinct presentation pathways, we examined a cell deficient in 
exogenous Ag presentation for its ability to process and present 
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Figure  3.  Ag presentation to GTH by cells secreting L  d does not occur by reuptake from the culture medium. (.4) 5  x  10  s irradiated din2 and 
BALB/c splenocytes (spin) were placed in culture with 7.5  x  10  4 GTH T calls in the presence or absence of La/Q10-containing  supematant (LD/Q10 
SN). DAP-ADLD and DAP-ADLD/Q10 were also examined for their ability to stimulate GTH providing positive controls.  (B) The Ag presentation 
assay was performed as described in the legend to Fig.  1 With the following modifications.  DAP-AD were preincubated for 4 d in the presence of 
Ld/Q10-containing  supernatant (DAP-LD/Q10 SN) or cultured for 4 d in the presence of Ld/Q10-secreting cells (DAP-LD/Q10) before initiation of 
the Ag presentation assay and incubation  with GTH.  5  x  104 APC and responder T cells were placed in triplicate wells of a 96-well plate. Shown 
are cpm incorporated by CTLL in a secondary culture. (C) LAd-bearing APC cultured in the presence of Ld/Q10 containing supernatant (LD/Q10 
SN) or La/Q10-secreting cells (DAP-LD/Q10)  sdmuhte the proliferation of a dm2 anti-BALB/c bulk CD4 + T cell population, dm2 mice were depleted 
of CD8 + T cells, then immunized with La-bearing BALB/c  splenocytes. 2.5  x  103 of the resulting T cells were then placed in microwells with 5 
x  10  3 mitomycin-treated L cells or 5  x' 103 irradiated splenocytes as indicated. After 48 h of incubation, T cell proliferation was measured as a func- 
tion of [3H]thymidine incorporation. (/9) Cell surface staining of cells used in coculture experiments. As indicated, single and mixed cell cuhures were 
stained for bad (  ) and L  d (  ) surface expression using the mAbs MKD6 and 30.5.7, respectively. After addition of the FITC-GAM  sec- 
ondary staining reagent, cells were fixed and histograms generated by FACScan  |  Control staining was performed using FITC-GAM  alone (  ....  ). 
(E) 5  x  104 GTH T cells were placed in microwells with varying numbers of DAP-AD APC exposed for 15 h to 0.05/~M purified Ld/Q10 (11). 
To examine for subthreshold levels of peptide-MHC complex at the APC surface, peptide dose-response  curves were generated using untreated APC 
([~) or APC pretreated with 0.05 #M purified La/Q10 (A). 
endogenous L  a, exogenous La/Q10, and synthetic L  a 61-85 
peptide. The lymphoblast tumor cell line ELAD (EL4 trans- 
fected with LA  d) (42) is unable to present exogenous Ag to 
OVA-specific  hybridomas  (Miller, J., unpublished observa- 
tions, and 49). Fig. 4 A demonstrates the inability of ELAD 
to stimulate the hMYO-specific, I-Ad-restricted  T  cell hy- 
bridoma ACHhMyo/27.7  in the presence of whole hMyo 
Ag. In the presence of MYOT, however, ELAD stimulated 
ACHhMyo/27.7  as effectively  as DAP-AD  (Fig.  4 B).  We 
also found ELAD incapable of presenting exogenous nominal 
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Ag to a panel of I-AS-restricted  hybridomas  while ELAD 
stimulated these same T cells when Ag processing was bypassed 
by providing peptide (data not shown). This indicates that 
the Ag presentation defect in ELAD is due to an intraceUular 
processing  event,  not to a defect in class II or in accessory 
molecule function. We next examined the ability of ELAD 
to process and present purified Ld/Q10.  As shown in Fig. 
5 D,  ELAD could not utilize exogenously added purified 
Ld/Q10 to generate peptide-MHC complexes sufficient for 
GTH stimulation. Moreover,  no shift was observed  when 1SCO00 ￿9 
O---  DAP-AD 
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Figure 4.  EL4 cells transfected with I-A  d cannot effectively  process and 
present nominal  Ag (A) but can present peptide (B). (A) ELAD and DAP- 
AD cells were incubated with 0.05 mg/ml of hMYO for 11 h, washed, 
fixed (0.1% paraformaldehyde x  20 min), and plated at varying numbers 
with  5  x  104  I-Ad-restricted,  hMYO-speciiic  T  cell  hybridomas 
(ACHhMYO/27.7).  (B) ELAD and DAP-AD APC were fixed as in A 
and  then incubated with  (10  /~g/ml)  of MYOT  in the  presence  of 
ACHhMYO/27.7. The number of APC per well was titrated while T 
cells were plated at 5  x  104 cells/well. T cell lymphokine production was 
measured by CTLL incorporation of [~H]thymidine. 
peptide dose-response curves were generated in the presence 
or absence of exogenously added soluble La/Q10 (Fig. 5 D, 
￿9  vs [2]). Thus, we conclude that ELAD are deficient in 
the  presentation  of nominal  Ag  including  exogenously 
provided La/Q10. 
To determine if ELAD can process and present internally 
derived L  d peptide, ELAD cells were supertransfected with 
the  gene  encoding L  a  (ELAD-LD)  and  tested  for  their 
ability to stimulate GTH. As shown in Fig. 5 C, these cells 
efficiently stimulated GTH suggesting that events critical for 
class II presentation  of internally synthesized  L  a are fun- 
damentally different from those critical for class II presenta- 
tion of exogenous Ag. A  similar conclusion  was recently 
reached by Bikoff (49) using this cell line. 
We considered several possibilities to explain this result. 
First, staining profiles for ELAD-LD and DAP-ADLD using 
several anti-I-A  a and anti-L  d mAbs (Fig. 5 A) demonstrate 
that the two APC have comparable expression of both the 
restriction dement and the target Ag. Second, it was pos- 
sible that ELAD effectively presented L  a because of an en- 
hanced avidity of ELAD for the GTH hybridoma. But when 
Ag processing is bypassed through addition of synthetic L  d 
61-85 peptide, ELAD and DAP-AD are nearly equivalent APC 
for GTH (Fig. 5 B). Finally, we considered the possibility 
that stimulation of GTH occurred because of supersaturating 
amounts of L  a peptide  generated by the internal route of 
presentation. This excess  would allow ELAD-LD to display 
peptides  derived  from internal  L  a at  threshold levels for 
T cell stimulation compared to subthreshold levels from pep- 
tides derived from exogenous Ag. To more accurately quan- 
tify the efficiency  of presentation, Ag presentation blocking 
experiments were performed using varying concentrations 
of anti-I-A d (M5114) mAb added to ELAD-LD or to con- 
trol DAP-ADLD APC (Fig. 5 F). Parallel blocking studies 
were performed in Ld-negative DAP-AD and ELAD cells 
using the L  a 61-85 peptide  (Fig.  5 E) to control for the 
adhesion/accessory properties of these APC. Antibody con- 
centrations capable of effecting a 50% reduction in the max- 
imal GTH response were then calculated for each APC. Based 
on these assays, we conclude that ELAD-LD processing and 
presentation of internally derived L  a is in fact approximately 
threefold more efficient than DAP-ADLD (Fig. 5, E and F). 
These data argue against the possibility that EL4 transfec- 
tants present internal L  d Ag, but not exogenous Ag, because 
endogenous Ag gain access  to the dass II presentation pathway 
more efficiently than exogenous Ag. These results, therefore, 
support  our hypothesis that the L  a peptide is generated by 
intracellular processing events that may differ from those typi- 
cally used to process exogenous Ag. 
Pancreatic Islet Cells Fail to Present Internally  Synthesized L d. 
Our experiments using EL4 suggest that presentation of ex- 
ogenous Ag by MHC class II is not a ubiquitous activity 
shared by all APC. We therefore examined a large pand of 
cells for the ability to present  the L d to  GTH to evaluate 
whether presentation of internally synthesized Ag is an ac- 
tivity universally shared by APC. One cell line tested, a pan- 
creatic islet cell line (/3TC-3 [H-2d]) (43) transfected with 
I-A  a (B-AD), can be induced to express high levels of MHC 
molecules upon treatment with IFN-'y and TNF (50, 51). 
The I-A  a islet transfectant was grown for 5 d in the pres- 
ence or absence of 10 U/ml IFN-3~ and 100 U/ml TNF and 
stained with mAbs reactive with L  a and  I-A  d.  Fig.  6 A 
shows that in untreated cells (M), the L  a surface staining is 
only slightly above background levels obtained with an ir- 
relevant control mAb. In contrast,  when cells are grown in 
the presence of cytokine, H-2L  d expression increases lO-20- 
fold. High levels of L  a surface expression were detected with 
both peptide-dependent  (30-5-7) and -independent (28-14- 
8) anti-L  a mAb (Fig. 6 A  and data not shown) suggesting 
that the MHC class I presentation pathway is functional in 
the cytokine-treated  cells. 
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Figure  5.  ELAD-LD efficiently presents the endogenously derived L  d target Ag. (A) DAP-ADLD and ELAD-LD express similar surface levels of 
both I-A  a and L  a. DAP-ADLD (a and b) and ELAD-LD (c and d) were stained with anti-class II (a and c) and anti-L  d (b and d) mAbs. For a and 
c, cells were  stained with the mAbs MKD6  (  ),  K24-199  (  ......... ), and 40B  (--).  (b and d) Staining with the mAbs 30.5.7 (anti-L  a) 
(  )  and 64.3.7  (anri-L  a) (--).  Background  staining  was performed using the irrelevant mAb 14.4.4S  and FITC-GAM.  (B)  ELAD and 
DAP-AD APC, fixed to pz~cent Ag processing, stimulate GTH similarly in the presence of L  a 61-85 peptide. APC, fixed by incubation in 0.1% parafor- 
maid￿9  for 20 rain, were plated at various cell concentrations with a constant number (5  x  104) of GTH T cells and 0.5 #M of L  a 61-85 peptide. 
(C) ELAD-LD stimulates GTH comparably to DAP-ADLD. F.LAD, ELAD-LD, and DAP-ADLD were plated at various cell concentrations with 5 
x  104 GTH T cells in an Ag presentation assay. (D) 5  x  104 ELAD APC were placed in an Ag presentation assay with increasing concentrations 
of purified La/Q10 (11) and examined for the ability to stimulate GTH. Peptide dose-response  curves were generated using ELAD APC, and GTH 
T  cells, and increasing concentrations  of L  d 61-85 peptide in the presence (A) or absence (1-7) of 0.05 #M La/Q10.  (E) M5114 (anti-l-A d) mAb was 
incubated at various concentrations  with 5  x  104 APC, 5  x  104 GTH T cells, and a suboptimal dose of L  d 61-85 peptide (0.025  #M). Results  are 
recorded as mean cpm of duplicate cultures. The initial M5114 dilution (10) corresponds to 100 #1 of mAb culture supernatant in a final vol of 200 
#1. Control cpm recorded in absence of M5114 are presented as points adjacent to the y-axis. (F) 5  x  104 of the indicated APC and 5  x  104 GTH 
T cells were incubated in an Ag presentation assay in the presence of decreasing concentrations of M5114. As in Fig. 5 E, the initial M5114 concentration 
was  100 #1 culture  supernatant in a final vol of 200 #1, and control  data points  (no mAb) are presented adjacent to the y-axis. 
Untreated islet cells (/3-AD [M]) did not stimulate GTH 
(Fig.  6 B) but did when provided  with exogenously added 
L  a peptide, indicating that the islet cells express sufficient ac- 
cessory molecules to effectively interact with the T  cell hy- 
bridoma. To determine whether increased target Ag expres- 
sion would permit B-AD to stimulate GTH, we induced L  a 
expression  with IFN-~/and TNF. Time course experiments 
demonstrated  that although islet cell L  d surface expression 
increased within 24 h of cytokine treatment,  presentation of 
internally  synthesized L  a did not  occur  even  after 5  d  of 
treatment  (Fig. 6 B). Nor was a shift in the L  d 61-85 pep- 
tide dose-response curve observed after induction of L a ex- 
pression (Fig.  6 B). Control experiments demonstrated  that 
TNF and IFN-3~ treatment  had no effect on/~-AD exoge- 
nous Ag presentation (Fig. 6, C and D) and did not antagonize 
exogenous or endogenous Ag presentation  in control APC 
(Fig.  6, E-H).  From these experiments, we conclude that 
expression  of endogenous  L  a within the  default  exocytic 
pathway and at the cell surface is insufficient for presentation 
of the target peptide to GTH. Rather, these data suggest that 
presentation of internally synthesized Ag by class II requires 
protein cofactors in addition to MHC class II, and that these 
cofactors may be differentially expressed in different cell types. 
Expression of a Leaderless Form of the  Target Ag Does Not 
Result in Stimulation of GTH.  Transmembrane viral Ag are 
proteolyzed in the cytosol and presented by class I molecules 
by a process that presumably employs a pool of viral Ag ineffec- 
tively translocated into the endoplasmic reticulum (ER) (52). 
Since presentation  of L a does not require either internaliza- 
tion from the plasma membrane or endocytic uptake from 
the  extracellular  medium,  we  next  sought  to  determine 
whether the cytosolic class I pathway is used to generate L  a 
peptides for I-A  a binding. If this was the case, we predicted 
three experimental  results: (a) a cytosolic form of L  d should 
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Figure  6.  (A) ~-AD transfectants were incubated 
for 5 d in the presence (TNF/IFN-'y) or absence (M) 
of TNF (100 U/ml) and IFN-3, (10 U/ml) and then 
evaluated  for MHC expression  by flow cytometry. Two- 
step immunofluorescence  staining was performed using 
the mAb 28.14.8 (anti-L  a) or an irrelevant  mAb (bach 
ground fluorescence) followed  by  FITC-GAM.  The 
resulting histograms are recorded as relative  cell number 
vs mean fluorescence intensity.  (B) B-AD does not 
present the endogenously derived determinant recog- 
nized by GTH, but effectively presents exogenously 
added La 61-85 peptide. APC were incubated at in- 
creasing cell numbers with 5  x  104 GTH T cells as 
previously described. (Q) GTH responses to varying 
numbers  of cytokine-treated  B-AD APC; (HI)  responses 
to untreated APC. The GTH response to increasing 
concentrations  of  synthetic  L  a 61-85  peptide  was 
evaluated using 5  x  104 cytokine-treated (4b) or un- 
treated control ([]) islet cell APC.  (C and D) Un- 
treated (D) or treated (￿9  TNF, 100 U/ml and IFN-q/, 
10 U/ml for 4 d) islet cell APC were incubated with 
5  x  104 54.8 T  cells and increasing concentrations 
of OVA (C) or OVAT (D). (E-H) Untreated (HI) and 
treated (~ ; TNF, 100 U/ml and IFN-3', 10 U/ml for 
5 d) DAP.3 transfectants w~re incubated in an Ag pre- 
sentation assay with 5  x  104 GTH (E and F) or 54.8 
(G and H) T  cells under the indicated conditions. 
stimulate GTH;  (b) expression  of Ii should block binding 
of target L d peptide to I-A  a and, as a result, inhibit stimu- 
lation of GTH; and (c) a cell line deficient in class I Ag pre- 
sentation  should  not  present  the L d target  peptide  and, 
therefore,  should not  stimulate GTH. 
To address the first hypothesis, we tested the ability of L cells 
expressing a cytosolic form of L  d to stimulate GTH.  A cyto- 
solic form of L a (La~) was generated using PCR mutagen- 
esis of a cDNA of L d to remove the sequence encoding the 
leader peptide. An initiation sequence was then added 5' to 
the  L d c~1  domain.  DAP-AD  cells  were  transfected  with 
genes encoding either La~ (DAP-ADLD~)  or wild-type L d 
cDNA (DAP-ADLDc)  in identical expression vectors. Un- 
like ceils expressing wild-type L  a, cells transfected  with Lacyt 
were unable to stimulate GTH (Fig. 7 A). In addition, pep- 
tide dose-response curves for DAP-AD and DAP-ADLDcyt 
were virtually identical (Fig. 7 B) suggesting no appreciable 
presentation of the cytoplasmic L a target Ag. The inability 
of Lay to gain access to the appropriate processing compart- 
ment indicates that cytosolic subsets of Ld/Q10 or wild-type 
L a that fail to translocate normally into the ER are unlikely 
to serve  as precursors  for the processed peptide recognized 
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Figure  7.  APC transfected  with 
a cytosolic form oftbe target Ag do 
not stimulate GTH. (/1) DAP-AD 
cells transfected with  cDNA en- 
coding  a cytoplasmic form of L  d 
(DAP-ADLDcy,) or  wild-type  L  a, 
cDNA (DAP-ADLDc) were exam- 
ined for their ability to stimulate 
GTH. The Ag presentation assay 
was performed as described in the 
legend  to  Fig.  1 using  5  x  104 
GTH  T  cells  and  increasing 
numbers of  APC per well. (B) Sub- 
threshold  levels of  the  L  a pep- 
tide-MHC complex are not present 
an equal number of APC per well. 
by GTH.  Thus,  unlike  the  results  of Townsend  et al.  (52) 
in their analysis of class I-restricted presentation  of a trun- 
cated cytosolic form of influenza hemagglutinin,  these results 
argue that class II-restricted presentation  of internally  syn- 
thesized  L a  does  not  occur  via  the  cytosolic  presentation 
pathway. 
Ii Expression  Has No Effect on Presentation of L a Peptide and 
Stimulation of GTH.  To test our second prediction,  we ex- 
amined  the effect of Ii on Ag presentation.  As a  subset  of 
L a is poorly transported out of the ER (53), it seemed plan- 
sible that resident ER proteolytic machinery (54) might pro- 
cess L a and generate peptides capable of binding newly syn- 
thesized class II molecules within the ER. Because experiments 
performed in vitro  have demonstrated  that  Ii inhibits  pep- 
tide binding  to class  II (16,  55,  56),  we reasoned  that  ER 
presentation  should be blocked in APC which express high 
levels of Ii (Fig. 8 A). We therefore examined L a peptide pre- 
sentation by Ltk-  APC  transfected with  bA  d and L a with 
and  without  genomic  Ii (LADgIi  and  LAD,  respectively). 
As  shown  in  Fig.  8  C,  the  Ii-positive and  -negative APC 
stimulated  GTH  similarly,  indicating  that Ag presentation 
of L d is independent  of Ii expression. 
A  Cell Line Deficient  in  Class  1-restricted Ag Presentation 
Presents the Internally  Synthesized L d by MHC  Class II.  To 
address whether  L a presentation  is dependent  on the func- 
tional TAP proteins which are important for class I Ag pre- 
sentation,  we examined the ability of a cell line deficient in 
MHC  class I assembly (EE2H3)  to stimulate GTH. EE2H3 
is an H-2  k embryonic cell line that is d~g~t  in the expres- 
sion of the putative peptide transporter TAP-1 and has a pheno- 
Figure  8.  Ii expression does not affect the presentation of endogenous L  d target Ag. (A) Immunoprecipitation of LADgli-LD  ceU lysates demon- 
strates saturating levels of Ii in association with class II. Cells were labeled for 30 rain with [3H]lencine and Ii precipitated from the lysates with the 
mAbs IN-1 and P4H5 (lane 3), whereas I-A  a was precipitated using the mAb MKD6 (lane 2). The proteins were separated on SDS-10% PAGE under 
reducing conditions. ([) p31 and p41 Ii forms; (--~) a  and B chains. (Lane 1) Demonstrates precipitation with an irrelevant mAb for comparison of 
nonspecific background bands. (B) Flow cytometry of Ii- LAD-LD (a and b) and Ii + LADgli-LD (c and d) transf~ctants was performed as previously 
described. For a and c, ceils were stained with the anti-chss II mAbs MKD6 (  ) (anti-loA  d, Ii-independent) and 40B (--)  (anti-Ia, Ii-dependent) 
(39, 40). (b and d) Surface staining using the anti-L  d mAbs 30.5.7 (  ) and 64.3.7 (--).  (  ......... ) Staining with an irrelevant mAb (14.4.4S, 
all panels). (C) Ii expression does not inhibit presentation of endogenous L  d to GTH. LAD and LADgli transfectants differing only in li expression 
were subsequently supertransfected with genomic L  d yielding LAD-LD and LADgli-LD, respectively.  These APC were then examined for their ability 
to stimulate GTH. Hybridomas were plated at 5  x  104 cells/well with varying numbers of APC. 
81  Loss et al. type resembling that of RMA-S (45, 57). EE2H3 was trans- 
fected with genes encoding L  a and bA  d and the resulting 
transfectants (EE2H3-ADLD) tested for the ability to stimulate 
GTH. As shown in Fig. 9, EE2H3-ADLD effectively stimu- 
lated  GTH  despite near background levels of L  d surface 
staining. In conjunction  with the results described above, these 
data suggest that class II-restricted presentation of L  d to 
GTH may not follow typical class I or II presentation pathways. 
Discunion 
Class II molecules are specialized to present peptides de- 
rived from exogenous Ag but are also capable of presenting 
peptides derived from proteins synthesized within the APC. 
Most of the studies addressing the mechanisms of class II 
Ag presentation have focused on the former (58, 59). These 
studies, in conjunction with those examining class II trafficking 
(60-62), the relationship between class II and Ii (16, 42, 55, 
56),  and the formation of stable class II dimers (63),  have 
led to the general model that class II binds to peptides de- 
rived from Ag that enter the APC by endocytosis and are 
proteolyzed within acidic vesicles of the endosomal/lysosomal 
pathway. Clearly, internally synthesized secretory or integral 
membrane proteins theoretically have access to the putative 
endosomal/lysosomal  processing pathway. However, it is be- 
coming increasingly dear that internal Ag may access endo- 
somes/lysosomes  by mechanisms other than endocytosis, in- 
cluding chaperone-mediated trafficking from the cytosol, 
autophagy from the cytosol and ER, and direct trafficking 
from the TGN. It is less clear whether the route by which 
an Ag enters the endosomal/lysosomal pathway affects the 
repertoire of peptides revealed (64), or if different routes em- 
ploy different processing cofactors. For example, prolonged 
Ag expression within the ER or Ag interaction with HSPs 
might influence processing such that the dominant epitopes 
generated are different from those revealed after endocytosis 
from the extracellular  fluid. 
We have established a model system designed to examine 
the mechanisms governing MHC class II presentation of an 
endogenous Ag. Unique to our system is the use of a target 
Ag (MHC class I, L  d) that is constitutively expressed by a 
variety of nucleated cells, providing us with the opportunity 
to study the processing requirements for a normally expressed 
protein in cells of different lineages. T cells recognizing this 
epitope are stimulated by unmanipulated BALB/c splenocytes 
indicating that this peptide-class II complex is not only one 
which APC can be designed to generate, but is also one which 
is naturally displayed in vivo. 
One possible explanation for the presentation of internally 
derived surface proteins by class II is that these proteins gain 
access to the endocytic pathway by internalization from the 
cell membrane. Using a secreted  form of L  d, we demon- 
strated that surface expression is not essential for L  d presen- 
tation. Experiments using purified soluble Ld/Q10 demon- 
strated that GTH was not stimulated even at Ag concentrations 
1,000-fold greater than those present in the culture medium 
of DAP-ADLD/Q10 transfectants.  Moreover,  dm2 spleno- 
cytes, which include cells considered to be professional APC, 
were unable to present the exogenously added soluble form 
of L  d. These results, coupled with those obtained in a series 
of coculture experiments, suggest that the secreted target Ag 
does not gain access to the class II presentation pathway by 
uptake from the extraceUular milieu. We are confident that 
4 d of coculture provided more than adequate  time to ac- 
cumulate MHC-peptide complexes at the cell surface because 
I-Ad-positive APC  transiently  transfected  with  L  d were 
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Figure  9.  (.4) EE2H3-ADLD stimulates GTH. 
EE2H3 cells transfected  with I-A  d and L d were ex- 
amined for their ability to stimulate GTH. DAP- 
ADLD and untransfected EE2H3 were examined 
in parallel as positive and negative controls, respec- 
tively. APC were plated at increasing cell numbers 
with 5  x  104 GTH T  cells.  (B) EE2H3-ADLD 
(H-2  k) express low levels of class I. EE2H3-ADLD 
(top) and DAP-ADLD (bottom) transfectants were 
stained with MKD6 (anti-l-A  a, - ........ ), 28.14.8 
(anti-L  d,  ), 16.1.11N (anti-K  k,  ) and 
with  an  irrelevant  antibody  14.4.4S  (,,~,~,-) 
followed by FITC-GAM as previously described. 
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not  shown).  The  finding  that  soluble  La/Q10  added  to 
I-Aa-bearing APC  resulted in  the  stimulation  of a  bulk 
population of CD4 + anti-BALB/c T cells demonstrates that 
peptide determinants other than those recognized by GTH 
were generated from Ld/Q10. Attempts to modulate L  a pro- 
cessing and presentation with exogenously added anti-L  d an- 
tibody proved ineffective using APC expressing either the 
cell surface form of L d or the secreted La/Q10  (data not 
shown). This is consistent with our hypothesis that a cell 
surface or extracellular intermediate is not involved in gener- 
ating the L d peptide recognized by GTH.  Moreover EL4, 
a cell line defective in exogenous Ag presentation, effectively 
processed and presented internally synthesized L d. Taken to- 
gether, these data support the hypothesis that processing of 
L a resulting in the peptide recognized by GTH takes place 
during biogenesis and intracellular transport of the target Ag. 
Our experiments also address whether the L a target Ag 
accesses dass I proteolytic machinery within the cytosol. Tram- 
fection of APC with a cytosolic form of L d did not result 
in stimulation of GTH. This is consistent with class II-re- 
stricted endogenous Ag presentation  systems reported by 
Brooks et al. (10) and Weiss and Bogen (7), although several 
studies have indicated that cytosolic proteins may gain access 
to class II if they are expressed at very high levels (6, 8). At- 
tempts to augment expression of La~yt by increasing gene 
copy number in a transient transfection assay or by regulating 
expression with the strong ~-actin promoter did not result 
in stimulation of GTH, nor was Ld~ presentation revealed 
by subjecting APC to serum starvation or heat shock (data 
not shown). These results suggest it is unlikely that improperly 
translocated L a plays  any role in  stimulation of GTH.  In 
support of this conclusion, transfectants of EE2H3 (45, 57), 
a cell line deficient in class I Ag presentation, effectively stimu- 
lated GTH. Finally, using three different cell types, we have 
found that Ii fails to block class II-restricted presentation of 
L d. It is therefore improbable that the classical class I pro- 
cessing  pathway generates  the  L a  peptide  recognized by 
GTH. 
One of the most intriguing results from this series of ex- 
periments relates to the differences observed between different 
cell types in exogenous and endogenous Ag presentation. A 
lymphobhst tumor cell line (EL4) defective in exogenous class 
II Ag presentation effectively stimulated GTH. In contrast, 
a pancreatic cell line (BTC-3) capable of exogenous Ag pre- 
sentation, was unable to present endogenous L a despite high 
surface expression of both the restriction element and the 
L a target Ag.  These results suggest  that  to  generate and 
present the L a peptide, it is insuffident to merely express the 
target Ag and the appropriate MHC class II restriction ele- 
ment.  Taken  together,  our  results  suggest  that  different 
cofactors may regulate endogenous and exogenous class II 
Ag presentation and that expression of these cofactors may 
be regulated in a tissue-specific  manner. This possibility is 
consistent with earlier work showing that some APC, differing 
in cell type or physiologic state, show differences in their ability 
to present epitopes derived from extracellular Ag (65, 66). 
Although the biological basis for the observed differences re- 
mains to be determined, our observations suggesting that 
different cell lines process and present Ag differently have 
potential implications for a number of immune phenomena 
including thymic selection, where different APC types are 
believed to be responsible for positive and negative selection, 
and autoimmune responses, where tissue-specific Ag presen- 
tation might play a role in the pathogenesis of localized, 
T  cell-mediated autoimmune disease. 
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